Market Overview

Covidien Announces Enrollment of First Patient in SWIFT PRIME Acute Ischemic Stroke Study

Covidien
(NYSE: COV) today
announced the launch of a new study, SWIFT PRIME, which enrolled its
first patient at the University at Buffalo. The new multi-center,
randomized controlled trial will be one of the largest global studies to
examine the adjunctive use of mechanical thrombectomy during the early
stages of acute ischemic stroke onset.

Covidien's Solitaire FR Revascularization Device will be used in the SWIFT PRIME Study (Photo: Business Wire)

Acute ischemic stroke occurs when a clot in a blood vessel blocks blood
supply to the brain. According to the American Heart Association, acute
ischemic stroke is the leading cause of disability and the fourth most
common cause

See full press release

Posted-In: News Guidance Management Global

 

Related Articles (COV)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters